MYD88 and Proinflammatory Chemokines in Aortic Atheromatosis: Exploring Novel Statin Effects
Atherosclerosis is driven by a diverse range of cellular and molecular processes. In the present study, we sought to better understand how statins mitigate proatherogenic inflammation. 48 male New Zealand rabbits were divided into eight groups, each including 6 animals. The control groups received n...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/11/9248 |
| _version_ | 1797597515680317440 |
|---|---|
| author | Konstantinos S. Mylonas Michail Peroulis Dimitrios Schizas Alkistis Kapelouzou |
| author_facet | Konstantinos S. Mylonas Michail Peroulis Dimitrios Schizas Alkistis Kapelouzou |
| author_sort | Konstantinos S. Mylonas |
| collection | DOAJ |
| description | Atherosclerosis is driven by a diverse range of cellular and molecular processes. In the present study, we sought to better understand how statins mitigate proatherogenic inflammation. 48 male New Zealand rabbits were divided into eight groups, each including 6 animals. The control groups received normal chow for 90 and 120 days. Three groups underwent a hypercholesterolemic diet (HCD) for 30, 60, and 90 days. Another three groups underwent HCD for 3 months, followed by normal chow for one month, with or without rosuvastatin or fluvastatin. The cytokine and chemokine expressions were assessed in the samples of thoracic and abdominal aorta. Rosuvastatin significantly reduced MYD88, CCL4, CCL20, CCR2, TNF-α, IFN-β, IL-1b, IL-2, IL-4, IL-8, and IL-10, both in the thoracic and abdominal aorta. Fluvastatin also downregulated MYD88, CCR2, IFN-β, IFN-γ, IL-1b, IL-2, IL-4, and IL-10 in both aortic segments. Rosuvastatin curtailed the expression of CCL4, IFN-β, IL-2, IL-4, and IL-10 more effectively than fluvastatin in both types of tissue. MYD88, TNF-α, IL-1b, and IL-8 showed a stronger downregulation with rosuvastatin compared to fluvastatin only in the thoracic aorta. The CCL20 and CCR2 levels reduced more extensively with rosuvastatin treatment only in abdominal aortic tissue. In conclusion, statin therapy can halt proatherogenic inflammation in hyperlipidemic animals. Rosuvastatin may be more effective in downregulating MYD88 in atherosclerotic thoracic aortas. |
| first_indexed | 2024-03-11T03:07:08Z |
| format | Article |
| id | doaj.art-f435579aa32741f5ba5977d56d79789c |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T03:07:08Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-f435579aa32741f5ba5977d56d79789c2023-11-18T07:56:24ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-05-012411924810.3390/ijms24119248MYD88 and Proinflammatory Chemokines in Aortic Atheromatosis: Exploring Novel Statin EffectsKonstantinos S. Mylonas0Michail Peroulis1Dimitrios Schizas2Alkistis Kapelouzou3Department of Cardiac Surgery, Onassis Cardiac Surgery Center, 176 71 Athens, GreeceVascular Surgery Unit, Department of Surgery, Faculty of Medicine, University of Ioannina, 451 10 Ioannina, GreeceFirst Department of Cardiac Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, 176 71 Athens, GreeceClinical, Experimental Surgery & Translational Research, Biomedical Research Foundation Academy of Athens, 176 71 Athens, GreeceAtherosclerosis is driven by a diverse range of cellular and molecular processes. In the present study, we sought to better understand how statins mitigate proatherogenic inflammation. 48 male New Zealand rabbits were divided into eight groups, each including 6 animals. The control groups received normal chow for 90 and 120 days. Three groups underwent a hypercholesterolemic diet (HCD) for 30, 60, and 90 days. Another three groups underwent HCD for 3 months, followed by normal chow for one month, with or without rosuvastatin or fluvastatin. The cytokine and chemokine expressions were assessed in the samples of thoracic and abdominal aorta. Rosuvastatin significantly reduced MYD88, CCL4, CCL20, CCR2, TNF-α, IFN-β, IL-1b, IL-2, IL-4, IL-8, and IL-10, both in the thoracic and abdominal aorta. Fluvastatin also downregulated MYD88, CCR2, IFN-β, IFN-γ, IL-1b, IL-2, IL-4, and IL-10 in both aortic segments. Rosuvastatin curtailed the expression of CCL4, IFN-β, IL-2, IL-4, and IL-10 more effectively than fluvastatin in both types of tissue. MYD88, TNF-α, IL-1b, and IL-8 showed a stronger downregulation with rosuvastatin compared to fluvastatin only in the thoracic aorta. The CCL20 and CCR2 levels reduced more extensively with rosuvastatin treatment only in abdominal aortic tissue. In conclusion, statin therapy can halt proatherogenic inflammation in hyperlipidemic animals. Rosuvastatin may be more effective in downregulating MYD88 in atherosclerotic thoracic aortas.https://www.mdpi.com/1422-0067/24/11/9248MYD88CCL4CCL20CCR2atherosclerosisstatin |
| spellingShingle | Konstantinos S. Mylonas Michail Peroulis Dimitrios Schizas Alkistis Kapelouzou MYD88 and Proinflammatory Chemokines in Aortic Atheromatosis: Exploring Novel Statin Effects International Journal of Molecular Sciences MYD88 CCL4 CCL20 CCR2 atherosclerosis statin |
| title | MYD88 and Proinflammatory Chemokines in Aortic Atheromatosis: Exploring Novel Statin Effects |
| title_full | MYD88 and Proinflammatory Chemokines in Aortic Atheromatosis: Exploring Novel Statin Effects |
| title_fullStr | MYD88 and Proinflammatory Chemokines in Aortic Atheromatosis: Exploring Novel Statin Effects |
| title_full_unstemmed | MYD88 and Proinflammatory Chemokines in Aortic Atheromatosis: Exploring Novel Statin Effects |
| title_short | MYD88 and Proinflammatory Chemokines in Aortic Atheromatosis: Exploring Novel Statin Effects |
| title_sort | myd88 and proinflammatory chemokines in aortic atheromatosis exploring novel statin effects |
| topic | MYD88 CCL4 CCL20 CCR2 atherosclerosis statin |
| url | https://www.mdpi.com/1422-0067/24/11/9248 |
| work_keys_str_mv | AT konstantinossmylonas myd88andproinflammatorychemokinesinaorticatheromatosisexploringnovelstatineffects AT michailperoulis myd88andproinflammatorychemokinesinaorticatheromatosisexploringnovelstatineffects AT dimitriosschizas myd88andproinflammatorychemokinesinaorticatheromatosisexploringnovelstatineffects AT alkistiskapelouzou myd88andproinflammatorychemokinesinaorticatheromatosisexploringnovelstatineffects |